# Single Dose, Pharmacokinetic, Safety, Tolerability and QTc Study of GSK1278863 in Healthy Volunteers

> **NCT02293148** · PHASE1 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 61 (actual)

## Conditions studied

- Anaemia

## Interventions

- **DRUG:** GSK1278863 75 mg
- **DRUG:** GSK1278863 500 mg
- **DRUG:** Moxifloxacin 400 mg
- **DRUG:** Placebo matching GSK1278863
- **DRUG:** Placebo matching Moxifloxacin

## Key facts

- **NCT ID:** NCT02293148
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-11-17
- **Primary completion:** 2015-03-10
- **Final completion:** 2015-03-10
- **Target enrollment:** 61 (ACTUAL)
- **Last updated:** 2018-07-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02293148

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02293148, "Single Dose, Pharmacokinetic, Safety, Tolerability and QTc Study of GSK1278863 in Healthy Volunteers". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02293148. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*